Navigation Links
Plasma-based treatment goes viral
Date:12/5/2011

Life-threatening viruses such as HIV, SARS, hepatitis and influenza, could soon be combatted in an unusual manner as researchers have demonstrated the effectiveness of plasma for inactivating and preventing the replication of adenoviruses.

When exposed to plasma the fourth state of matter in addition to solids, liquids and gases for a period of just 240 seconds, it was found that only one in a million viruses could still replicate practically all were inactivated.

The study, published in IOP Publishing's Journal of Physics D: Applied Physics, is one of the first to concentrate specifically on viruses and builds on research that has already shown the usefulness of plasma in eradicating bacteria from skin (http://www.iop.org/news/09/november/page_42357.html) and sterilising water (http://www.iop.org/news/11/nov/page_52641.html).

Within a hospital environment, a plasma generating device could realistically rid hands of potentially lethal viruses that relay on a host organism to replicate and spread. In the long-term, plasma could be inhaled directly to treat viruses in the lungs, or applied to blood outside of the body to remove any viruses before transfusion.

The researchers, from the Max-Planck Institut fr extraterrestrische Physik and Technische Universitt Mnchen, specifically chose adenoviruses to examine as they are one of the most difficult viruses to inactivate. Illnesses resulting from this specific virus, for example, can only be managed by treating symptoms and complications of the infection, rather than targeting the actual virus itself.

Adenoviruses predominantly cause respiratory illnesses such as pneumonia and bronchitis and are hard to inactivate as the whole virus is encased in a protein layer, helping it to remain physically stable and tolerate moderate increases in
'/>"/>

Contact: Michael Bishop
michael.bishop@iop.org
01-179-301-032
Institute of Physics
Source:Eurekalert

Page: 1 2

Related biology news :

1. Phase I trial begins using gene therapy and bone marrow stem cells in the treatment of brain cancer
2. Novel monoclonal antibody offers potential treatment for tumors resistant to VEGF therapy
3. Fish flu: Genetics approach may lead to treatment
4. Possible treatment target found for main cause of severe liver disease in kids
5. Texas A&M center confronts antibiotic crisis with potential new bacterial treatment
6. Evidence for spinal membrane as a source of stem cells may advance spinal cord treatment
7. Dormant malaria parsites in red blood cells may contribute to treatment failure
8. British study may improve glaucoma assessment and treatment
9. Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody for the Treatment of Autoimmune Diseases
10. UT Southwestern research could lead to new treatments for IBD, viral infections
11. Cracking breast cancers genetic code may lead to new treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... N.Y. A billion people living in underdeveloped areas ... that survive by residing in and feeding on their ... systemic) illnesses leading to long-term disability. Irah King and ... investigating illnesses caused by these gut-dwelling worms in an ...
... Mo. Americans spend $25 billion a year on ... While the Nutrition Business Journal forecasts that sales of ... over the next five years, scientists still don,t know ... harmful to humans. Now, with a new $7.5 million ...
... Max Planck Institute for Chemical Ecology in Jena, Germany, ... pending for 40 million years. Arum palaestinum ... flies) as pollinators by emitting odor molecules that resemble ... by yeast. The plant accomplishes the illusion of yeast ...
Cached Biology News:Studying illnesses caused by worms: Scientists are learning how immune cells communicate 2MU establishes National Botanical Research Center 2Deceitful lily fools flies 2Deceitful lily fools flies 3
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... LAKE CITY, Feb. 29 DW Healthcare ... announced today the sale of one,of its ... Laboratory,Corporation of America(R) Holdings (LabCorp(R)), one of ... Salt Lake City, UT, Tandem,Labs is a ...
... Feb. 29 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... biopharmaceutical company focused on,endocrine therapy and oncology, ... the Company,s Senior Vice President, Administrative & ... accepted the position of,Vice President and Chief ...
... On Friday, February 29, the Johnson & Johnson ... the U.S., designed to improve how,practitioners deliver diabetes care ... be devoted to training community health,professionals., Diabetes affects ... billion a year -- about as much as the ...
Cached Biology Technology:AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs 2MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care 2
... 220-240 V, is used for biolistic particle ... device employs an adjustable helium pulse to ... microcarriers from the inner wall of a ... This system has a 2 square-centimeter target ...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
Mouse monoclonal antibody raised against a partial recombinant NR4A2. NCBI Entrez Gene ID = NR4A2...
Biology Products: